Dyne Therapeutics, Inc. filings document regulatory disclosures for a clinical-stage neuromuscular disease company advancing FORCE platform programs. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary cash-resource disclosures, investor presentation materials, clinical and FDA-related updates, and other business highlights tied to Duchenne muscular dystrophy and myotonic dystrophy type 1 programs.
The company’s definitive proxy materials cover board structure, director elections, executive compensation, equity awards, stockholder voting matters and governance practices. Other filings address board appointments, non-employee director compensation arrangements and Nasdaq-related inducement equity awards.
ForDyne B.V., an affiliate of DYN, filed a notice of proposed sales of DYN common stock under Rule 144. The filing lists 261,460 shares of common stock that may be sold through UBS Financial Services Inc. on Nasdaq, with a filing date of 07/27/2026.
The notice also reports recent sales by ForDyne B.V. over the past three months, including multiple transactions in June 2026 with disclosed share amounts and aggregate values.
Dyne Therapeutics is conducting a primary offering of 18,300,000 shares of common stock at $20.50 per share, for a gross offering size of $375,150,000. Underwriters have a 30-day option to purchase up to 2,745,000 additional shares. Shares outstanding will be 183,831,839 after the offering, or 186,576,839 if the option is fully exercised.
Net proceeds are estimated at $352.1 million, or $405.0 million with full option exercise, to be used with existing cash and a $50.0 million Hercules term loan tranche to advance Phase 3 programs z-rostudirsen (DMD) and z-basivarsen (DM1), pursue regulatory approvals, build manufacturing and commercial infrastructure, fund other neuromuscular and FORCE platform R&D, and for working capital. The company expects its capital, including this raise and the Hercules borrowing, to fund operations, debt service and capex into the second quarter of 2028.
Dyne highlights recent progress: initiation of Phase 3 FORZETTO (DMD) and HARMONIA (DM1) trials and U.S. FDA acceptance of a BLA for z-rostudirsen with Priority Review and a PDUFA target action date of January 21, 2027. The company also outlines covenant constraints under its up to $400.0 million Hercules loan facility, including minimum cash and revenue covenants tied to market capitalization and product sales.
Dyne Therapeutics entered into an underwriting agreement for an underwritten public offering of 18,300,000 shares of common stock at a public price of $20.50 per share, with underwriters purchasing at $19.27 per share. The company also granted the underwriters a 30‑day option to buy up to 2,745,000 additional shares at the public price less underwriting discounts and commissions.
The company estimates net proceeds of approximately $352.1 million, or approximately $405.0 million if the option is fully exercised, after underwriting discounts and estimated expenses. The offering is being made under an automatically effective shelf registration statement on Form S‑3, with closing expected on or about July 23, 2026, subject to customary conditions. Dyne believes these net proceeds, together with existing cash, cash equivalents and marketable securities and a $50.0 million term loan tranche borrowed from Hercules Capital in June 2026, will enable it to fund operating expenses, debt service obligations and capital expenditures into the second quarter of 2028, while cautioning that this forward‑looking runway estimate depends on various assumptions and risks.
Dyne Therapeutics, Inc. is conducting a primary offering of $300,000,000 of common stock, with a 30‑day option for underwriters to buy up to an additional $45,000,000 of common stock. Its shares trade on the Nasdaq Global Select Market under the symbol DYN; the last reported sale price on July 20, 2026 was $23.45 per share.
The company is a clinical‑stage developer of therapies for genetically driven neuromuscular diseases built on its FORCE platform, with lead programs in Duchenne muscular dystrophy (z‑rostudirsen) and myotonic dystrophy type 1 (z‑basivarsen), both in global Phase 3 trials. The FDA has accepted a biologics license application for z‑rostudirsen, granted Priority Review, and set a PDUFA target action date of January 21, 2027.
Dyne plans to use the equity proceeds, together with existing cash and a recently drawn $50.0 million term loan from Hercules, to fund clinical development, regulatory work, manufacturing and commercial build‑out, platform and pipeline R&D, and general corporate purposes. Management currently expects these resources to fund operating expenses, debt service and capital expenditures into the second quarter of 2028, subject to business and development outcomes.
Dyne Therapeutics, Inc. announced that the U.S. Food and Drug Administration has accepted for review its biologics license application for zeleciment rostudirsen (z‑rostudirsen, also known as DYNE‑251) to treat individuals with Duchenne muscular dystrophy amenable to exon 51 skipping. The FDA granted Priority Review and set a Prescription Drug User Fee Act target action date of January 21, 2027.
The company stated it continues to expect a potential U.S. launch of z‑rostudirsen in the first quarter of 2027, assuming approval is received on this anticipated timeline. Dyne also emphasized that these expectations are forward‑looking and subject to substantial risks and uncertainties, including clinical, regulatory and financing factors described in its SEC reports.
Dyne Therapeutics, Inc. director-affiliated venture funds completed open-market sales of a combined 777,451 shares of common stock on July 6–7, 2026. The trades, at weighted-average prices between about $22.79 and $23.62 per share, were executed under a Rule 10b5-1 trading plan adopted on March 19, 2026.
The shares were sold by Atlas-managed funds, including Atlas Venture Fund XI and Atlas Venture Opportunity Funds, in which director Jason P. Rhodes participates through general partner entities. He disclaims Section 16 beneficial ownership beyond any pecuniary interest. After the transactions, these funds continue to hold multimillion-share positions, such as 2,962 shares in one Atlas vehicle.